Previous 10 | Next 10 |
Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
While the market has mainly sold-off this month, four biotech stocks have showed strength in anticipation of successful drug candidates: Arena Pharmaceuticals (ARNA), Fate Therapeutics (FATE), Kura Oncology (KURA), and Stoke Therapeutics (STOK). The biotech sector has received a lot of at...
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Cantor Virtual Global H...
Stoke Therapeutics ( STOK +0.3% ) has announced the publication of preclinical data of STK-001 that demonstrated significant improvements in survival and reductions in seizure frequency in a mouse model of Dravet syndrome. Data were published in Journal Science Translational...
STK-001 has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome A Phase 1/2a study of STK-001 in children and adolescents ages 2 to 18 years old is now underway Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company ...
Dr. Menzel brings significant leadership in the global healthcare sector Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointmen...
Stoke Therapeutics (NASDAQ: STOK ) : Q2 GAAP EPS of -$0.39 misses by $0.04 . More news on: Stoke Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– First patient dosed with STK-001 in Part A of Phase 1/2a MONARCH clinical trial for Dravet syndrome – – Company on track to identify an additional pre-clinical candidate derived from its TANGO platform for the treatment of an additional genetic disease in 2H 2020...
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that members of management will present at three upcoming investor conferences in August: ...
Gainers: Global Eagle Entertainment ENT +164% . More news on: Hamilton Beach Brands Holding Company, Wilhelmina International, Inc., Oncternal Therapeutics, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...